NCT01965145

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Institut de Recherches Internationales Servier · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis exacerbations

Detailed description

A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis

Conditions

• Behcet's Uveitis

Interventions

Type	Name	Description
DRUG	Gevokizumab	Sterile solution administered subcutaneously
DRUG	Placebo	Sterile solution administered subcutaneously

Timeline

• Start date: 2012-11-01
• Primary completion: 2015-07-01
• Completion: 2015-09-01
• First posted: 2013-10-18
• Last updated: 2020-01-03

Locations

2 sites across 2 countries: South Korea, United Kingdom